Who are we ?

Founded in 1969, CIT is a privately-owned, global pharmaceutical development CRO. From our offices in France and the United States, we offer comprehensive IND enabling programs for biologics and small molecules therapeutics.

Our broad range of GLP discovery services, help our customers meet the demands of today's complex global marketplace. We can help you accelerate product development, expand into new markets, mitigate risk, reduce regulatory delays and improve quality. CIT study reports have been successfully used by our clients in support of marketing authorization and new drug approval submissions to te European (EMEA), US (FDA) and Japanese (MHLW) regulatory authorities.

CIT is committed to the humane treatment of the research animals entrusted to our care. We guarantee they will be treated with the highest standards of respect and compassion with particular attention to socialization and enrichment. CIT's Ethics Committee has established and rigorously enforces our Ethics Charter for Laboratory Animals. All employees must continually demonstrate their commitment to animal welfare and are required to sign our Ethics Charter as a condition of initial and continuig employment. Since 2004, our high moral and ethical standards have been recognized by the American Association of Laboratory Animal Care (AAALAC).

3422 toxicology studies including 105 carcinogenicity studies

                                                910 reprotoxicology studies

1088 pharmacokinetic studies

                                              23 143 short term studies

114 genomic related endpoints and biodistribution studies

                                            135 ICH, TCR and biodistribution studies